French pharmaceutical group Ipsen (EPA: IPN) has announced net profits of 190.7 million euros ($2017. 3 million) for the last financial year, 2015.
The figure shows a 23% increase on the previous 12-month period and a 25.3% increase in earnings per share to 2.78 euros. The board has proposed a dividend of 0.85 euros per share.
The annual report revealed sound cash flow generation with closing cash of 214.0 million euros. Full year group sales were up 10.4% to 1.44 billion euros up from 1.27 euros in 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze